Erudio Healtherudio.com
Drug
Belantamab mafodotin trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying belantamab mafodotin: DREAMM-10 and PrE1005. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 6 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| PrE1005 NCT07285239 · PrECOG, LLC. | newly diagnosed multiple myeloma | Phase 3 | 28 | 3 | Focused | Oct 29, 2026 | Preview |
| DREAMM-10 NCT06679101 · GlaxoSmithKline | transplant-ineligible, newly diagnosed multiple myeloma | Phase 3 | 406 | 41 | Deep | Oct 28, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DREAMM-7 NCT04246047 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-8 NCT04484623 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-3 NCT04162210 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-9 NCT04091126 · GlaxoSmithKline DeepView → | newly diagnosed multiple myeloma | Phase 1 | Deep | View | |||
| DREAMM-6 NCT03544281 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| BelaRd NCT04808037 · Hellenic Society of Hematology FocusedView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 1/Phase 2 | Focused | View | |||